Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Toxic Protein Complexes Promote Development of Multiple Neurodegenerative Disorders

By LabMedica International staff writers
Posted on 15 Sep 2008
Neuroscientists have identified a mechanism that explains why patients suffering from severe neurodegenerative diseases such as Alzheimer's disease often develop other syndromes such as Parkinson's disease and vice versa.

The mechanism is linked to the misfolding and pathologic aggregation of neuronal proteins, which has been proposed to play a critical role in the pathogenesis of neurodegenerative disorders. More...
Progressive accumulation of amyloid beta protein (Abeta) oligomers has been identified as one of the central toxic events in Alzheimer's disease, while accumulation of alpha-synuclein (alpha-syn) results in the formation of oligomers and protofibrils in Parkinson's disease.

Investigators from the University of California, San Diego (San Diego, CA, USA) used immunoblots, molecular modeling, and in vitro studies performed with alpha-syn and Abeta in order to understand the molecular mechanisms involved in potential Abeta/alpha-syn interactions. They reported in the September 4, 2008, issue of the journal Public Library of Science (PLoS) ONE that Abeta and alpha-syn co-immunoprecipitated and formed complexes. Molecular modeling and simulations showed that Abeta bound alpha-syn monomers, homodimers, and trimers, forming hybrid ring-like pentamers. Interactions occurred between the N-terminus of Abeta and the N-terminus and C-terminus of alpha-syn. The stable pentamers acted as nanopores that altered neuronal activity and would likely contribute to the mechanisms of neurodegeneration in Alzheimer's and Parkinson's diseases.

"Clinically, we knew that having one neurological disease, such as Alzheimer's, put patients at risk for another neurological disease in combination with it, for example, Parkinson's disease or frontotemporal dementia. But as doctors and scientists, we did not understand why this occurred until now,” explained senior author Dr. Eliezer Masliah, professor of neurosciences and pathology at the University of California, San Diego. "This sort of modeling, to determine the structure of these complexes, was never before possible. With this novel technology, we have come to a new understanding of these combined neurological diseases, and have a model for developing new drugs to treat them.”

Related Links:
University of California, San Diego



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.